SJSiriphailin Jomjunyoung

Siriphailin Jomjunyoung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siriphailin Jomjunyoung has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toward a National Tuberculosis Lateral-Flow Urine Lipoarabinomannan (LF-LAM) External Quality Assessment Program in Thailand: Feasibility Demonstration Through Panel Development, Validation, and Proficiency Testing, March 2025–April 2026

    by Supaporn Suparak, Theerawit Tasaneeyapan, Petai Unpol, Sirilada Pimpa Chisholm, Siriphailin Jomjunyoung, Kanokwan Ngueanchanthong, Wipawee Thanyacharern, Nitis Smanthong, Thanapatra Klawech, Phitchamon Thongthirach, et al.

    Background: The World Health Organization and the Thailand National HIV Treatment Guidelines recommend the use of lateral flow urine lipoarabinomannan (LF-LAM) testing for tuberculosis (TB) detection in people living with HIV (PLHIV) with advanced HIV disease who have signs and symptoms of TB or are seriously ill. As Thailand decentralizes LF-LAM testing, a robust quality assurance system is needed to maintain diagnostic accuracy across healthcare levels. Methods: We developed, validated, and rolled out Thailand’s first national external quality assessment (EQA) and internal quality control (IQC) framework for urinary TB LF-LAM testing. Pre-characterized urine panels were distributed to 20 provinces spanning 12 health regions nationwide across four cycles from 2025 to 2026. Longitudinal monitoring of reporting compliance, pass rates, and failure modes was performed across 30 participating sites in 2025 and 64 and 42 sites in 2026 Rounds 1 and 2, respectively. Results: IQC coverage increased from 7 to 68 facilities by the final cycle in January 2026, with satisfaction rates of 85.7–100%. EQA pass rates showed a stepwise improvement: 83.3% in Round 1/2025, 93.1% in Round 2/2025 and 97.5% and 98.4% in the 2026 rounds (p < 0.05). Initial failures were primarily due to false-positive interpretation of Grade 1 bands and deviation in the reading window. Targeted retraining and standardized reference match-cards reduced user-dependent false-positive results to 0% in the final cycle. Conclusions: A centralized national quality assurance framework may be an effective mechanism for standardizing the reliability and interpretation of point-of-care LF-LAM testing across decentralized healthcare systems. This approach strengthens diagnostic capacity at peripheral facilities and supports the safe expansion of TB services for PLHIV.

  • Open Access

    Development and Evaluation of a Lyophilized Plasma-Based Internal Quality Control for Human Immunodeficiency Virus Rapid Diagnostic Tests

    by Siriphailin Jomjunyoung, Wanvisa Treebuphachatsakul, Supaporn Suparak, Nam K. Tran, Gerald J. Kost, Napaporn Apiratmateekul

    Background/Objectives: Rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV) are widely used, but most kits lack standardized internal quality control (IQC) materials. In this study, we aimed to develop and evaluate a plasma-based IQC compatible with five HIV RDT brands and with proven long-term stability. Methods: Control samples at three reactivity levels were tested with five HIV RDT kits in lyophilized and liquid forms. Lyophilized samples were produced with and without trehalose, whereas liquid samples were prepared with and without StabilZyme™ SELECT Stabilizer (Stabilizer). Accelerated stability testing was performed at 37 °C and 45 °C for 28 days, and the most stable formulation was selected for long-term storage at 4 ± 2 °C and 25 ± 5 °C. Stability was assessed based on test-line visibility and signal intensity. Signal-intensity trends were analyzed using simple linear regression with a t-test on the slope; samples were considered stable when no significant trend was detected (p > 0.05). Results: Reactivity measured using the Elecsys HIV combi PT assay yielded cutoff index (COI) values of 772.65 (1:8) for the strong-positive control and 269.95 (1:25) for the weak-positive control. Trehalose-containing lyophilized samples maintained reactivity under accelerated testing at 37 and 45 °C and for 6 months at 4 ± 2 °C and 25 ± 5 °C, with no significant change in signal intensity (p > 0.05). Conclusions: The plasma-based IQC materials were compatible with all five HIV RDTs, and trehalose-stabilized lyophilized plasma showed high stability, supporting transport and storage without strict cold-chain requirements.


  • Open Access

    Innovating Quality Control and External Quality Assurance for HIV-1 Recent Infection Testing: Empowering HIV Surveillance in Lao PDR

    by Supaporn Suparak, Kanokwan Ngueanchanthong, Petai Unpol, Siriphailin Jomjunyoung, Wipawee Thanyacharern, Sirilada Pimpa Chisholm, Nitis Smanthong, Pojaporn Pinrod, Thitipong Yingyong, Phonepadith Xangsayarath, et al.

    Quality assurance programs are critical to ensuring the consistency and reliability of point-of-care surveillance test results. In 2022, we launched Laos’ inaugural quality control (QC) and external quality assessment (EQA) program for national HIV recent infection surveillance. Our study aims to implement the first QC and EQA program for national HIV recent infection surveillance in Laos, utilizing non-infectious dried tube specimens (DTS) for quality control testing. This initiative seeks to monitor and assure the quality of HIV infection surveillance. We employed the Asante HIV-1 Rapid Test for Recent Infection (HIV-1 RTRI) point-of-care kit, using plasma specimens from the Thai Red Cross Society to create dried tube specimens (DTS). The DTS panels, including HIV-1 negative, HIV-1 recent, and HIV-1 long-term samples, met ISO 13528:2022 standards to ensure homogeneity and stability. These panels were transported from the Thai National Institute of Health (Thai NIH) to the Laos National Center for Laboratory and Epidemiology (NCLE) and subsequently shipped to 12 remote laboratories at ambient temperature. The laboratory results were electronically transmitted to Thai NIH 15 days after receiving the panel for performance analysis. The concordance results with the sample types were scored, and laboratories that achieved 100% concordance across all sample panels were considered to have satisfactorily met the established standards. Almost all laboratories demonstrated satisfactory results with 100% concordance across all sample panels during all three rounds of QC: 11 out of 12 (92%) in June, 10 out of 12 (83%) in July, and 11 out of 12 (91%) in August. The two rounds of EQA performed in June and August 2022 were satisfied by 8 out of 11 (72%) and 5 out of 10 (50%) laboratories, respectively. QC and EQA monitoring identified errors such as testing protocol mistakes and insufficient DTS panel dissolution, leading to improvements in HIV recency testing quality. Laboratories that reported errors were corrected and implemented further preventive actions. The QC and EQA program for HIV-1 RTRI identified errors in HIV recent infection testing. Implementing a specialized QC and EQA program for DTS marks a significant advancement in improving the accuracy and consistency of HIV recent infection surveillance. Continuous assessment is vital for addressing recurring issues.


  • Open Access

    Evaluation of the HIV-1 Rapid Recency Assay and Limiting Antigen Avidity Enzyme Immunoassay for HIV Infection Status Interpretation in Long-Term Diagnosed Individuals in Thailand

    by Supaporn Suparak, Petai Unpol, Kanokwan Ngueanchanthong, Siriphailin Jomjunyoung, Wipawee Thanyacharern, Sirilada Pimpa Chisholm, Nitis Smanthong, Thitipong Yingyong, Pilailuk Akkapaiboon Okada

    Background/Objectives: Accurate surveillance of recent HIV infections is crucial for effective epidemic control and timely intervention. The Limited Antigen Avidity Enzyme Immunoassay (LAg-EIA) allows precise differentiation between recent and long-term HIV infections. To enhance accessibility, it has been developted into a point-of-care test, the Asanté™ HIV-1 Rapid Recency® Assay (ARRA), a rapid immunoassay. This study evaluated the performance and false recent rates (FRRs) of the ARRA, interpreted both visually and via a strip reader, in comparison with the LAg-EIA. Methods: Plasma samples were collected from two groups: 634 long-term HIV-infected individuals, identified through routine diagnostic testing, who had not received antiretroviral therapy for over one year, and 224 individuals from high-risk populations. High-risk individuals, including pregnant women, female sex workers, and men who have sex with men, were selected based on behavioral and demographic risk factors. Concordance between the ARRA and LAg-EIA was assessed, and FRRs were calculated for both assays. McNemar’s test was used to evaluate agreement, while Spearman’s rho was applied to assess correlation between the two methods. Results: Visual interpretation of ARRA demonstrated perfect agreement with LAg-Avidity EIA results (FRR = 0.00%), while the strip reader misclassified two specimens as recent infections (FRR = 0.32%). McNemar’s test indicated no significant differences between the methods (p > 0.05). Moderate agreement (Spearman’s rho = 0.434) was observed between ARRA strip reader results and LAg-Avidity EIA optical density values. Among high-risk populations, ARRA misclassified one sample as recent, resulting in an inconsistency rate of 0.45%. Conclusions: This study highlights ARRA’s reliability in identifying long-term infections and its potential as a point-of-care tool. Its rapid results and ease of use make it a valuable asset for effective HIV surveillance, facilitating targeted epidemic monitoring and enhancing public health interventions.


  • Open Access

    Establishing Quality Assurance for HIV-1 Rapid Test for Recent Infection in Thailand through the Utilization of Dried Tube Specimens

    by Supaporn Suparak, Petai Unpol, Kanokwan Ngueanchanthong, Sirilada Pimpa Chisholm, Siriphailin Jomjunyoung, Wipawee Thanyacharern, Nitis Smanthong, Pojaporn Pinrod, Kriengkrai Srithanaviboonchai, Thitipong Yingyong, et al.

    The present study focuses on establishing the quality assurance of laboratories for recent infections (RTRI) in Thailand. We developed a cold-chain independent method, using fully characterized plasma obtained from the Thai Red Cross Society, and prepared as dried tube specimens (DTS). Twenty microliters of HIV-seronegative, recent, and long-term infected samples were aliquoted into individual tubes and dried at room temperature, 20–30 degrees Celsius, in a biosafety cabinet overnight to ensure optimal preservation. The DTS external quality control and external quality assessment were tested for homogeneity and stability following the ISO/Guide 35 guidelines. The DTS panels were distributed to 48 sites (FY 2022) and 27 sites (FY 2023) across 14 and 9 provinces, respectively, in Thailand. The results from participating laboratories were collected and evaluated for performance. The results were scored, and acceptable performance criteria were defined as the proportion of panels correctly tested, which was set at 100%. The satisfactory performance ranged from 96% to 100% and was not significantly different among the 13 health regions. The developed and implemented DTS panels can be used to monitor the quality of RTRI testing in Thailand.